1-[3-(二甲基氨基)丙基]吡咯烷-2-酮 | 7375-15-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-[3-(二甲基氨基)丙基]吡咯烷-2-酮
• 英文名称: 1-[3-(dimethylamino)propyl]pyrrolidin-2-one
• 英文别名: 1-(3-dimethylaminopropyl)-2-pyrrolidone；N-(Dimethylaminopropyl)butyrolactam
• CAS: 7375-15-7
• 化学式: C₉H₁₈N₂O
• 分子量: 170.255
• InChiKey: VBRBLUHWCNINSZ-UHFFFAOYSA-N

物化性质

• 沸点：
  299.91°C (rough estimate)
• 密度：
  1.0114 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-[3-(二甲基氨基)丙基]吡咯烷-2-酮 在 硝酸丙酯 、 lithium diisopropyl amide 作用下， 生成
  参考文献：
  名称：

  Nouveaux 5-nitroimidazoles à noyau lactame hautement actifs : préparation et propriétés antibactériennes

  摘要：

  New 5-nitroimidazoles bearing a trisubstituted ethylenic double bond in position 2 were prepared by reacting various 1-alkyl-2-chloromethyl-5-nitroimidazole with 3-nitrolactam anions by S(RN)1 mechanism in phase-transfer catalysis conditions. These compounds showed in vitro and in vivo antianaerobic activity which was clearly greater than that of metronidazole. Structure-activity relationships have been discussed.

  DOI：

  10.1016/0223-5234(91)90118-7
• 作为产物：
  描述：

  1,1-二甲基-2-丙基肼 、 水 生成 1-[3-(二甲基氨基)丙基]吡咯烷-2-酮
  参考文献：
  名称：

  Process for preparing spirocyclic lactams

  摘要：

  本发明涉及一种改进的制备螺环内酰胺的方法，该方法利用二碘化物在N-取代了三级胺基团的内酰胺的螺烷基化反应中。所得的螺环内酰胺在生产各种取代的氮杂螺环烷中有用，这些化合物可用作免疫调节剂。

  公开号：

  US05734061A1

文献信息

• COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME
  申请人：Midatech Limited

  公开号：US20150099698A1

  公开（公告）日：2015-04-09

  Nanoparticles having a core and a corona of ligands covalently linked to the core, wherein differing species of peptides are bound to the nanoparticles and incorporated into various dosage forms.

  纳米颗粒具有核心和与核心共价连接的配体环，其中不同种类的肽与纳米颗粒结合，并纳入各种剂型中。
• TRPV1 agonist compounds and methods for making and using the same
  申请人：Jamieson Curtis Gene

  公开号：US20060240097A1

  公开（公告）日：2006-10-26

  Described here are TRPV1 agonist compounds and their methods of synthesis and use. In addition to specifically identified compounds, capsaicin prodrugs, gemini dimers, and mutual prodrugs are also described. Formulations of the TRPV1 agonist compounds may be in the form of a liquid, tablets, capsules, gel, cream, emulsion, a patch, or the like. Methods for treating medical conditions using the compounds, compositions, or prodrugs described, are also provided.

  这里描述了TRPV1激动剂化合物及其合成和使用方法。除了具体识别的化合物外，还描述了辣椒素前药、双子星二聚体和相互前药。TRPV1激动剂化合物的配方可以是液体、片剂、胶囊、凝胶、乳霜、乳状液、贴片等形式。还提供了使用所述化合物、组合物或前药治疗医疗状况的方法。
• [EN] CARBOXYLIC DITHIOCARBAMIC ACID ANHYDRIDE COMPOUNDS AND COMPOSITIONS THEREOF<br/>[FR] COMPOSÉS D'ANHYDRIDE D'ACIDE DITHIOCARBAMIQUE CARBOXYLIQUE ET COMPOSITIONS DE CEUX-CI
  申请人：FUNDACIO INSTITUT CATALA DINVESTIGACIO QUIM ICIQ

  公开号：WO2021144395A1

  公开（公告）日：2021-07-22

  The present invention relates to certain carboxylic dithiocarbamic acid anhydride compounds compounds and their use as photoinitiators in living free-radical polymerization reactions. The invention also relates to curable or cross-linkable compositions comprising the carboxylic dithiocarbamic acid anhydride compounds of the invention.

  本发明涉及某些羧基二硫代氨基甲酸酐化合物以及它们在活性自由基聚合反应中作为光引发剂的用途。该发明还涉及包括本发明的羧基二硫代氨基甲酸酐化合物的可固化或可交联组合物。
• CARBOXY ESTER KETALS, METHODS OF MANUFACTURE, AND USES THEREOF
  申请人：SEGETIS, INC.

  公开号：US20140147395A1

  公开（公告）日：2014-05-29

  This disclosure is directed to compound of formula (1): wherein R 1 is a C 7-18 alkyl, R 2 is hydrogen or a C 1-3 alkyl, each R 3 , R 4 , R 5 , R 6 , and R 7 is independently hydrogen or a C 1-6 alkyl, a is 2-3, and b is 0-1, its method of preparation and uses thereof in water-borne coating compositions, cleaning compositions, fragrance, and personal care compositions.

  这项披露涉及到化合物的结构式(1)：其中R1是C7-18烷基，R2是氢或C1-3烷基，每个R3、R4、R5、R6和R7独立地是氢或C1-6烷基，a为2-3，b为0-1，以及其在水性涂料组合物、清洁组合物、香料和个人护理组合物中的制备方法和用途。
• [EN] USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES<br/>[FR] UTILISATION DE PROMÉDICAMENTS DE CANNABIDIOL POUR ADMINISTRATION TOPIQUE ET TRANSDERMIQUE AVEC DES MICRO-AIGUILLES
  申请人：ALLTRANZ INC

  公开号：WO2011026144A1

  公开（公告）日：2011-03-03

  Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.

  本文描述了微针药物递送系统，包括含有药物活性成分（例如大麻二酚和大麻二酚前药）的药物组合物和适用于将活性成分局部或全身性递送至哺乳动物的微针阵列。本文还描述了使用微针经皮或局部药物递送系统治疗疾病，包括胰腺炎和胰腺癌的方法，其中药物组合物包括大麻二酚和大麻二酚前药，并且使用微针阵列。